Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03634241 | Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04479306 | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 |
| clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
| NCT01118676 | Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03446547 | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)(ASTEROID) | completed | Phase 2 | 106 | Vastra Gotaland RegionOTHER_GOV | 3 | Apr 14, 2026 | clinicaltrials |
| NCT05826366 | Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | completed | — | 296 | AstraZenecaINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07526961 | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland | completed | — | 240 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05106374 | Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer | completed | — | 182 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03523702 | The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial(SPRINT) | completed | Phase 2 | 25 | Montefiore Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07143513 | Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | completed | — | 102 | AmgenINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 101 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05387512 | Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer | completed | — | 60 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03589547 | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung(358) | completed | Phase 2 | 11 | Brown UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05873439 | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | completed | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04677595 | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-C) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03678350 | Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04351256 | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy(TRADE-hypo) | completed | Phase 2 | 51 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03915951 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 98 | PfizerINDUSTRY | 5 | Mar 24, 2026 | clinicaltrials |
| NCT04484142 | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | completed | Phase 2 | 137 | Daiichi SankyoINDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT07490639 | Family-Supported Palliative Care in Advanced Lung Cancer(FSPC-LC) | completed | N/A | 110 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07475637 | Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer(LBM-T790M) | completed | — | 70 | Faculty of Medicine of TunisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 | Mar 18, 2026 | clinicaltrials |
| NCT02504372 | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)(PEARLS) | completed | Phase 3 | 1,177 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
| NCT02818920 | Neoadjuvant Pembrolizumab(TOP 1501) | completed | Phase 2 | 35 | Neal Ready MD PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | completed | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01647867 | Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers(MetLung) | completed | N/A | 56 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02448758 | Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)(CB(NPC)²) | completed | — | 518 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06525246 | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer | completed | Phase 1 | 78 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06282991 | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | completed | — | 73 | PfizerINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07215026 | Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes(UNCOVER) | completed | — | 833 | AstraZenecaINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04912687 | Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients(CIRCULAR) | completed | N/A | 581 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07432308 | Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC(Liquid biopsy) | completed | N/A | 22 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01279408 | Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) | completed | — | 46 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03083041 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 210 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04900363 | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | completed | Phase 1 / Phase 2 | 108 | AkesoINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02738398 | FDG PET/CT in Lung Cancer Staging | completed | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03564197 | 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC | completed | N/A | 80 | The Netherlands Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03724331 | Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience | completed | N/A | 235 | University of NebraskaOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05263947 | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation | completed | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Medical University of South CarolinaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2026source: clinicaltrials